Publisher disclosure: This article is published by LevelsRx, a telehealth provider that offers weight-management services. Our services are referenced below. Please weigh this commercial relationship when reading our recommendations.
This content is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting, stopping, or switching any weight-loss medication. Never discontinue a prescribed medication without speaking to your prescriber first.
All the prescription medications discussed here require a prescription from a licensed healthcare provider. Eligibility is determined case by case following a medical evaluation.
In This Guide
- Why Might Someone Stop Taking Wegovy?
- Side Effects and Safety: What to Know First
- Wegovy Alternatives Comparison Table for 2026
- Top Prescription Wegovy Alternatives
- Zepbound vs Wegovy: The Head-to-Head Data
- Over-the-Counter Options
- Do Natural Alternatives to Wegovy Work?
- Compounded Semaglutide: What Changed in 2025 and 2026
- How to Switch to an Alternative Safely
- Choosing the Right Substitute for You
- Frequently Asked Questions
Key Takeaways
Q: What are the main alternatives to Wegovy for patients facing cost or access barriers? A: FDA-approved options include Zepbound (tirzepatide), Saxenda (liraglutide), Qsymia (phentermine/topiramate ER), Contrave (naltrexone/bupropion), and orlistat. These differ substantially in mechanism, average trial results, administration route, and cost.
Q: Which alternative has shown the greatest average weight loss in clinical trials? A: In the SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine in 2025, tirzepatide (Zepbound) produced average weight loss of 20.2% of body weight at 72 weeks, compared with 13.7% for semaglutide 2.4 mg. Individual results vary.
Q: Are there effective over-the-counter alternatives? A: Alli (orlistat 60 mg) is the only FDA-approved OTC weight-loss medication, and trial data associates it with roughly 3–5% body weight loss when combined with a reduced-calorie, low-fat diet. Fibre supplements and green tea extract have limited evidence for meaningful weight loss.
Q: Can lifestyle approaches produce meaningful results? A: Structured nutrition, physical activity, and behavioural therapy have an established evidence base and can produce clinically meaningful weight reduction for many people, though on average less than GLP-1 pharmacotherapy in trial settings.
Q: How do patients switch to an alternative safely? A: Any switch should be planned and supervised by your prescriber, who will consider timing, titration, and your medical history. Weight regain after stopping GLP-1 therapy is well documented, which is why a transition plan matters.
Q: Is compounded semaglutide still an option? A: For most patients, no. The FDA declared the semaglutide shortage resolved in February 2025, ending the broad legal basis for compounding copies. Compounded semaglutide is not FDA-approved. See the dedicated section below.
Q: What is the strongest oral option? A: Among oral medications, Qsymia (phentermine/topiramate ER) has shown the greatest average weight loss in clinical trials, in the range of 8–10% of body weight, at a lower cost than injectable GLP-1s.
Why Might Someone Stop Taking Wegovy?
Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management, but it is not the right fit for every patient long-term.
Common Medical Reasons
- Persistent gastrointestinal side effects: Nausea, vomiting, diarrhoea, and constipation are common. For some patients these do not resolve even with gradual dose titration.
- Pancreatitis or gallbladder issues: GLP-1 receptor agonists carry warnings for acute pancreatitis and gallbladder disease. Patients who develop these conditions are typically advised to discontinue treatment.
- Thyroid contraindications: Semaglutide carries a boxed warning regarding thyroid C-cell tumours, based on rodent studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
- Inadequate response: Some individuals do not achieve meaningful weight loss, prompting reassessment of the treatment plan.
Practical and Financial Barriers
- Cost without insurance: Wegovy’s list price exceeds $1,300 per month. Many commercial plans and Medicare Part D plans exclude coverage for weight-loss medications.
- Supply and access issues: Although the FDA declared the semaglutide shortage resolved in February 2025, individual pharmacy availability and insurance formulary changes can still disrupt access.
- Injection preference: Weekly self-injection is a barrier for patients who would prefer an oral medication.
Stopping Wegovy does not mean giving up on weight management. Several alternatives exist across prescription, over-the-counter, and lifestyle categories — but the choice should be made with a prescriber.
Side Effects and Safety: What to Know First
This section appears before the efficacy data deliberately. Every medication discussed below carries risks, and those risks should inform your decision as much as the weight-loss figures.
GLP-1 receptor agonists (Wegovy, Zepbound, Saxenda): Common side effects include nausea, vomiting, diarrhoea, and constipation, most pronounced during dose escalation. Less common but serious risks include pancreatitis, gallbladder disease, kidney injury from dehydration, and severe gastrointestinal reactions. Semaglutide, tirzepatide, and liraglutide all carry a boxed warning regarding thyroid C-cell tumours and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2. They are not recommended in pregnancy.
Qsymia (phentermine/topiramate ER): Contraindicated in pregnancy due to topiramate’s risk of birth defects, and available only through a restricted REMS programme. May cause cognitive effects such as difficulty concentrating, along with increased heart rate, paraesthesia, and insomnia.
Contrave (naltrexone/bupropion): Carries a boxed warning for suicidal thoughts and behaviours associated with bupropion. Contraindicated in uncontrolled hypertension, seizure disorders, and with opioid use.
Orlistat (Xenical/Alli): Commonly causes oily stools, flatulence, and faecal urgency, particularly when dietary fat intake is high. Not suitable for patients with chronic malabsorption syndrome or cholestasis.
None of these medications is “safe” in an unqualified sense. Each was well tolerated by many participants in clinical trials, and each carries documented risks. Your prescriber should review your full medical history before recommending any of them.
Wegovy Alternatives Comparison Table for 2026
Results vary. The weight-loss figures below are averages from clinical trials of each medication, generally studied alongside diet and exercise. They describe study populations, not any individual, and are not results attributable to any telehealth programme. Costs are approximate cash prices as of publication and change frequently.
| Medication | Active Ingredient | Mechanism | Route | Avg. Weight Loss in Trials | Rx Required | Approx. Monthly Cost (cash) |
| Wegovy | Semaglutide 2.4 mg | GLP-1 receptor agonist | Weekly injection | ~15% (STEP programme) | Yes | $1,300+ |
| Zepbound | Tirzepatide | GIP/GLP-1 dual agonist | Weekly injection | ~20% (SURMOUNT-5, 72 wks) | Yes | $1,000+ |
| Saxenda | Liraglutide 3.0 mg | GLP-1 receptor agonist | Daily injection | ~5–8% | Yes | $1,200+ |
| Contrave | Naltrexone/bupropion | Opioid antagonist + dopamine/NE reuptake inhibitor | Oral, twice daily | ~5–6% | Yes | $200–$400 |
| Qsymia | Phentermine/topiramate ER | Sympathomimetic + anticonvulsant | Oral, daily | ~8–10% | Yes | $150–$250 |
| Xenical / Alli | Orlistat | Lipase inhibitor | Oral, with meals | ~3–5% | Xenical: yes / Alli: no | $50–$200 |
No single alternative matches Wegovy on every dimension. Tirzepatide leads on average trial efficacy, Qsymia offers the strongest oral results, and orlistat provides an accessible entry point without a prescription. A licensed provider can help you weigh these against your medical history, budget, and goals.
Top Prescription Wegovy Alternatives
Each FDA-approved medication below works through a different mechanism, which means patients who do not tolerate one drug may respond differently to another.
Zepbound (Tirzepatide)
Zepbound is the brand name for tirzepatide, FDA-approved for chronic weight management. It activates both GLP-1 and GIP receptors. In the SURMOUNT clinical trial programme, tirzepatide at the highest doses was associated with average weight loss of approximately 18–21% of body weight, making it the most effective prescription option currently approved for weight management based on available trial data.
Saxenda (Liraglutide 3.0 mg)
Saxenda is an earlier GLP-1 receptor agonist requiring daily rather than weekly injection. Average weight loss in trials is more modest, approximately 5–8% of body weight. It has a longer post-approval track record. Its shorter half-life means the drug clears the system more quickly, which some prescribers consider relevant if side effects arise, though this has not been established as a comparative tolerability advantage in head-to-head trials.
Qsymia (Phentermine/Topiramate ER)
Qsymia combines an appetite suppressant with an anticonvulsant that also reduces food cravings. Taken orally once daily, it has demonstrated average weight loss of 8–10% of body weight in clinical trials. Key considerations:
- Contraindicated in pregnancy due to topiramate’s risk of birth defects
- May cause cognitive side effects such as difficulty concentrating
- Available only through a restricted REMS programme for prescribers and pharmacies
- Generally lower cost than injectable GLP-1 medications
Contrave (Naltrexone/Bupropion)
Contrave acts on brain pathways involved in reward and hunger. Average weight loss in trials is approximately 5–6% of body weight. Because bupropion is also an antidepressant, some prescribers consider it for patients with co-occurring depression, though it carries a boxed warning for suicidal thoughts and behaviours and requires careful screening.
Telehealth platforms including LevelsRx connect patients with licensed providers who can evaluate medical history, determine eligibility, and monitor treatment. Whether any specific medication is appropriate for you is a clinical decision your prescriber must make.
Zepbound vs Wegovy: The Head-to-Head Data
This is the most frequently discussed comparison in weight management, and as of 2025 there is direct trial evidence rather than only cross-trial estimates.
Mechanism of Action
Wegovy activates the GLP-1 receptor, which slows gastric emptying and increases satiety signalling. Zepbound activates both GLP-1 and GIP receptors. Researchers hypothesise that dual receptor activity contributes to the greater average weight loss observed, though the precise mechanisms behind the difference are still being studied.
Efficacy: Direct Trial Evidence
The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, randomised 751 adults with obesity and without type 2 diabetes to the maximum tolerated dose of tirzepatide or semaglutide 2.4 mg over 72 weeks:
- Tirzepatide (Zepbound): average weight change of −20.2%
- Semaglutide 2.4 mg (Wegovy): average weight change of −13.7%
- A greater proportion of tirzepatide participants reached weight-loss thresholds of 10%, 15%, 20%, and 25%
Results vary. These are trial averages from a specific study population under trial conditions, including protocol-directed lifestyle support. Your results may be higher or lower, and depend on dose tolerance, adherence, medical history, diet, and physical activity.
Both drugs produced clinically meaningful weight loss. The trial was open-label, which is a methodological limitation worth noting.
Side Effect Profiles
Both medications share common gastrointestinal side effects including nausea, diarrhoea, vomiting, and constipation. In SURMOUNT-5, gastrointestinal events were the most common adverse events in both groups, and serious adverse events occurred in 4.8% of the tirzepatide group and 3.5% of the semaglutide group. Both drugs carry the same class-level boxed warning regarding thyroid C-cell tumours, and both carry warnings for pancreatitis.
Cost and Access
List prices for both exceed $1,000 per month, and insurance coverage varies significantly by plan. Both manufacturers have offered direct-to-consumer purchase programmes at reduced cash prices. Ask your provider and your insurer about current options, and check both manufacturers’ official savings programmes to see whether you qualify.
Over-the-Counter Options
Several options are available without a prescription, though expectations should be calibrated accordingly.
Alli (Orlistat 60 mg)
Alli is the only FDA-approved OTC weight-loss medication. It reduces absorption of a portion of dietary fat in the gut.
- Average weight loss of approximately 3–5% of body weight when combined with a reduced-calorie, low-fat diet
- Common side effects include oily stools, flatulence, and faecal urgency, especially when fat intake exceeds recommended levels
- Available at most pharmacies at roughly $50–$60 per month
- Not suitable for patients with chronic malabsorption syndrome or cholestasis
Fibre-Based Supplements
Glucomannan, psyllium husk, and other soluble fibres expand in the stomach and may promote fullness. Clinical evidence for meaningful weight loss is limited. They may help reduce overall calorie intake when taken before meals with adequate water, and are generally inexpensive and well tolerated.
Caffeine and Green Tea Extract
Caffeine has a modest, short-term thermogenic effect, and green tea extract standardised for EGCG has shown small effects on fat oxidation in some trials. Neither has been shown to produce weight loss comparable to prescription medications, and the clinical significance of these effects for body weight is uncertain.
What OTC Products Cannot Do
No over-the-counter product has been shown to replicate the effects of GLP-1 receptor agonists. Products marketed as “natural Ozempic” or “herbal semaglutide” have no clinical basis for those claims, and such marketing has drawn regulatory attention. Patients expecting double-digit percentage weight loss from supplements alone are likely to be disappointed.
Do Natural Alternatives to Wegovy Work?
Some lifestyle strategies have genuine clinical support. Many popular supplements do not.
Evidence-Supported Strategies
- Higher-protein dietary patterns: Increasing protein intake influences appetite-regulating hormones including ghrelin and PYY, and higher-protein diets are associated with increased satiety in controlled feeding studies. This is a dietary strategy, not a pharmacological equivalent to GLP-1 therapy.
- Time-restricted eating: Randomised trials of time-restricted eating have produced mixed results. Some show modest weight reduction; a notable randomised trial published in the New England Journal of Medicine in 2022 found that time-restricted eating combined with calorie restriction produced weight loss that was not significantly different from calorie restriction alone. The evidence does not currently support time-restricted eating as superior to standard calorie reduction.
- Regular physical activity: Combining 150–300 minutes of moderate-intensity aerobic activity per week with resistance training improves body composition and cardiometabolic markers. Exercise alone typically produces modest weight reduction but is strongly associated with maintaining weight loss achieved by other means.
- Behavioural therapy: Cognitive behavioural therapy focused on eating behaviours has demonstrated weight-loss benefits in clinical trials, particularly for patients whose eating patterns involve emotional or binge eating.
Supplements With Limited Evidence
- Berberine: Sometimes marketed as “nature’s Ozempic,” a comparison with no scientific basis. Berberine has shown modest effects on blood glucose and lipids in some studies. Effects on body weight in available studies are small and are not comparable to GLP-1 medications.
- Conjugated linoleic acid (CLA): Some studies suggest a small reduction in body fat, but results are inconsistent and the effect size is small.
- Apple cider vinegar: Evidence for weight loss is limited and drawn largely from small studies with methodological limitations.
Lifestyle approaches work best as part of a comprehensive plan. For patients who need more than lifestyle change alone, a consultation with a licensed provider can clarify whether pharmacotherapy is clinically appropriate.
Compounded Semaglutide: What Changed in 2025 and 2026
Compounded medications are not FDA-approved and have not been evaluated for safety, efficacy, or quality by the FDA.
Much of the information circulating online about compounded semaglutide is out of date. Here is the current position.
Federal law generally prohibits pharmacies from producing copies of a commercially available FDA-approved drug. A key exception applied while a drug was on the FDA’s shortage list, which is why compounded semaglutide became widely available between 2022 and 2024.
- The FDA declared the tirzepatide shortage resolved in December 2024, with enforcement grace periods ending in February and March 2025.
- The FDA declared the semaglutide shortage resolved in February 2025, with grace periods ending in April and May 2025.
- In April 2026, the FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, which would close the remaining pathway for large-scale compounding.
- Throughout 2026, the FDA issued multiple rounds of warning letters to telehealth companies over claims that compounded GLP-1 products are equivalent to, or approved in the same manner as, brand-name drugs.
What this means: compounded semaglutide is not a routine lower-cost substitute for Wegovy, and we do not present it as one. A compounded preparation is not FDA-approved, has not been evaluated by the FDA for safety, efficacy, or quality, and is not therapeutically interchangeable with Wegovy regardless of what it contains. Narrow patient-specific compounding may remain permissible where a prescriber documents a clinical need that an approved product cannot meet — this is a clinical determination, not a pricing decision.
The FDA has received hundreds of adverse event reports associated with compounded semaglutide and tirzepatide, including dosing errors by patients measuring doses from multidose vials, some requiring hospitalisation.
How to Switch to an Alternative Safely
Never stop Wegovy or start a new medication without medical guidance. The information below describes general clinical practice and is not a protocol for you to follow on your own.
Step 1: Consult Your Prescriber First
Your provider needs to assess your current health status, the reason for switching, and any contraindications for the new therapy. Telehealth consultations through platforms including LevelsRx can make this step more accessible for patients without easy access to an in-person obesity medicine specialist.
Step 2: Understand the Transition Timeline
The approach depends on which alternative you are moving to. In general terms:
- Switching to another GLP-1 or GIP/GLP-1 agonist: Prescribers commonly initiate the new medication at its lowest starting dose the week after the last Wegovy injection, and titrate according to the new drug’s labelling. Prior semaglutide dose does not typically translate to an equivalent starting dose of a different drug.
- Switching to an oral medication: These are generally started according to the labelled titration schedule for that medication, on a timeline your prescriber determines.
- Transitioning to lifestyle-only management: Some prescribers taper where dose strengths permit. This approach has not been formally studied, and appetite typically returns as the medication clears.
Step 3: Monitor for Weight Regain
Weight regain after stopping GLP-1 therapy is well documented. In the STEP 1 trial extension published in Diabetes, Obesity and Metabolism in 2022, participants regained approximately two-thirds of their lost weight in the year after semaglutide was withdrawn, with cardiometabolic improvements largely reverting as well.
To reduce this risk, prescribers commonly recommend:
- Beginning the alternative treatment on a timeline your provider specifies relative to your last Wegovy dose
- Reinforcing dietary and activity habits during the transition
- Tracking weight, appetite, and any new side effects during the first months
- Scheduling follow-up appointments so your provider can adjust the plan
Step 4: Adjust Expectations
If you are moving from Wegovy to a medication with lower average trial efficacy, some weight regain may occur even with good adherence. That does not necessarily mean the new treatment has failed. Discuss with your provider what a realistic outcome looks like for you.
Choosing the Right Substitute for You
Decision Factors to Evaluate
| Factor | Questions to Ask Yourself |
| Weight-loss goal | What degree of weight reduction would meaningfully improve my health, according to my provider? |
| Side effect experience | Did I experience side effects on Wegovy? Am I open to another GLP-1, or do I want a different drug class? |
| Route of administration | Am I comfortable with injections, or do I strongly prefer an oral medication? |
| Budget | What can I afford monthly at maintenance dosing? Do I have insurance coverage? |
| Comorbidities | Do I have type 2 diabetes, cardiovascular disease, depression, seizure history, or other conditions that affect which medications are appropriate? |
| Long-term plan | Am I looking for ongoing treatment, or a bridge while building sustainable habits? |
Matching Profiles to Options
- Greatest average trial efficacy, comfortable with injections: Zepbound (tirzepatide) has the strongest head-to-head data.
- Prefer oral medication, moderate goals: Qsymia has shown the greatest average weight loss among oral options.
- Cravings and reward-driven eating are a primary concern: Contrave’s mechanism targets these pathways, subject to its contraindications and boxed warning.
- Prefer to avoid prescription drugs: A structured plan combining nutrition, physical activity, and behavioural support is the most evidence-backed non-pharmacological approach. Orlistat may be added, with realistic expectations.
Which of these is appropriate for you is a clinical decision. This list is not a recommendation for any individual.
The Value of Professional Guidance
Obesity is recognised as a chronic medical condition, not a matter of willpower. Working with a qualified provider helps ensure the alternative you choose is appropriate given your health history. Whether you consult your primary care physician, an endocrinologist, or a telehealth obesity medicine provider, professional input matters.
Frequently Asked Questions
What is the closest drug to Wegovy?
Zepbound (tirzepatide) is the closest in mechanism and the only alternative with direct head-to-head trial data against semaglutide. It targets the GLP-1 receptor plus the GIP receptor. For patients seeking semaglutide specifically, Ozempic contains the same active ingredient as Wegovy but is FDA-approved for type 2 diabetes rather than weight management, and prescribing decisions rest with your provider.
Can I switch from Wegovy to Zepbound without a gap?
Often, yes, but this must be managed by your prescriber. Prescribers commonly initiate tirzepatide at its lowest starting dose following the last Wegovy dose. A washout period is not typically required. Do not attempt to plan this transition yourself.
Are there Wegovy alternatives covered by insurance?
Coverage varies widely by plan. Oral medications such as Qsymia and Contrave often have better formulary placement than GLP-1 injectables for weight management. Some plans cover Zepbound, particularly where a qualifying comorbidity is documented. Contact your insurer directly for accurate information about your specific plan.
Is compounded semaglutide the same as Wegovy?
No. A compounded preparation is not FDA-approved and has not been evaluated by the FDA for safety, efficacy, or quality. It is not therapeutically interchangeable with Wegovy and should not be described as equivalent. Following the resolution of the semaglutide shortage in February 2025, the broad legal basis for compounding copies of semaglutide no longer applies.
Will I gain weight back if I stop Wegovy without starting an alternative?
Clinical evidence indicates that most patients regain a significant portion of lost weight within roughly a year of stopping GLP-1 therapy without another intervention. This is why a transition plan agreed with your provider matters before discontinuing.
Are natural supplements a realistic replacement for Wegovy?
No supplement has been shown to produce weight loss comparable to Wegovy. A comprehensive approach combining nutrition, regular physical activity, adequate sleep, stress management, and behavioural therapy can produce clinically meaningful results for many people. Supplements such as berberine or fibre have limited evidence and should not be relied on as standalone treatments.
How do I get started with a Wegovy alternative?
The first step is a consultation with a healthcare provider experienced in weight management. Telehealth platforms including LevelsRx offer virtual evaluations, prescribing where clinically appropriate, and ongoing monitoring. Eligibility is determined case by case, and not everyone who applies will qualify for medication.
Reminder: This content is for informational purposes only and does not constitute medical advice. All prescription medications discussed carry risks and require evaluation by a licensed provider. Individual results vary.
